Nasal congestion

Altamira Therapeutics Provides Update on Clinical Trials with Bentrio

Retrieved on: 
Tuesday, January 24, 2023
Nasal congestion, Virus, Particle-size distribution, Safety, Rhinitis, ANCOVA, Sudden death, COVID-19, Sneeze, Rhinorrhea, Allergen, Therapy, Omicron, Degenerative disease, CT, SAR, Research, Allergic rhinitis, Patient, Nasal mucosa, PCR, Incidence, NASAR, Severe acute respiratory syndrome coronavirus 2, Nasal spray, Pharmaceutical industry

The treatment effect of 1.55 points in favor of Bentrio was statistically significant in the ANCOVA model (LSmeans; p = 0.015; 95% confidence interval -2.78 to -0.32).

Key Points: 
  • The treatment effect of 1.55 points in favor of Bentrio was statistically significant in the ANCOVA model (LSmeans; p = 0.015; 95% confidence interval -2.78 to -0.32).
  • The interim analysis further showed good tolerability and safety both for Bentrio and the comparator.
  • Participants were randomized at a 1:1 ratio to either receive Bentrio or saline spray via self-administration three times per day, or as needed.
  • “We are very excited about the strong efficacy signals observed with Bentrio at the halfway point of the NASAR seasonal allergic rhinitis trial in Australia,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman, and CEO.

Global Inhalation and Nasal Spray Generic Drugs Market Report 2022 to 2028: Rapid Rise in Asthma Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Health, Pharmaceutical, Inhalation, Smoker, Respiratory disease, Tightness, Degenerative disease, Public health, Bronchitis, Demography, Cough, Health, Mouth, Conditional sentence, Nasal spray, Asthma, Inflammation, Disorder, Nasal congestion, Myalgia, Nose, Angina, Incidence, Market share, Exercise, Wheeze, Pharmaceutical industry

The "Global Inhalation and Nasal Spray Generic Drugs Market Size, Share & Industry Trends Analysis Report By End-user, By Indication, By Distribution Channel, By Demographics, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Inhalation and Nasal Spray Generic Drugs Market Size, Share & Industry Trends Analysis Report By End-user, By Indication, By Distribution Channel, By Demographics, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Inhalation and Nasal Spray Generic Drugs Market size is expected to reach $29.9 billion by 2028, rising at a market growth of 8.5% CAGR during the forecast period.
  • Inhalation and nasal spray generic drugs refer to a family of medicines that are consumed through the nose.
  • There are two types of nasal spray viz a conventional spray and a pump spray.

Nasal Drug Delivery Systems Global Market Report 2023: Increasing R&D of Nasal Delivery Bodes Well for Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023
Health, Pharmaceutical, GlaxoSmithKline, Region, Pain, Pfizer, Merck & Co., Rhinitis, Food, Market share, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Knowledge, Container (type theory), Allergy, Merck, Nasal congestion, CDMO, AstraZeneca, Johnson & Johnson, US, Growth, Novartis, Nasal cavity, Becton, Dickinson and Company headquarters, Distribution, FDA, Duane syndrome, Dosage form, Sinusitis, Marketing, Pharmaceutical industry

The nasal drug delivery systems used in the treatment of pain, acute migraine treatment, allergic and non-allergic rhinitis, and nasal congestion brought on by sinusitis, the common cold, or rhinitis.

Key Points: 
  • The nasal drug delivery systems used in the treatment of pain, acute migraine treatment, allergic and non-allergic rhinitis, and nasal congestion brought on by sinusitis, the common cold, or rhinitis.
  • Increasing research and development activities for nasal drug delivery systems is expected to drive growth of the global nasal drug delivery system market over the forecast period.
  • Furthermore, increasing product approvals by regulatory authorities is expected to drive growth of the nasal drug delivery market over the forecast period.
  • TYRVAYA Nasal Spray is the first and only nasal spray approved for the treatment of dry eye disease.

Nasal Drug Delivery Market Report 2022-2028: Increasing Patients Pool of Asthma and COPD Drives Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 28, 2022
Health, Pharmaceutical, Government, Ageing, COPD, AAFA, Pocs, Concept, Depression, Brain, Nasal congestion, Gel, CDNF, Growth, 3M, Patient, AstraZeneca, BD (company), Chronic obstructive pulmonary disease, FDA, Hospital, Merck Group, Asthma and Allergy Foundation of America, Prevalence, Pharmaceutical industry, Marketing, Asthma

The global nasal drug delivery market is anticipated to grow at a substantial CAGR of 5.5% during the forecast period.

Key Points: 
  • The global nasal drug delivery market is anticipated to grow at a substantial CAGR of 5.5% during the forecast period.
  • The rising prevalence of Asthma and chronic obstructive pulmonary disease (COPD) are factors that are driving the market growth.
  • Increasing patients pool of asthma and COPD across the globe are factors that increase the demand for nasal drugs for the treatment of diseases in the market.
  • The nasal drug delivery is segmented on the basis of dosage form, containers, therapeutic application, and end-user.

Afrin® WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays – Because One Sick Kid Can Throw Everything Off in An Instant

Retrieved on: 
Thursday, November 17, 2022
Health, Consumer, Parenting, Other Health, General Health, Pharmaceutical, R, Nasal spray, Parent, Trust, Common, Allergy, Nose, Bayer, Ageing, Child, Nasal congestion, Growth, Extrapyramidal system, Capital expenditure, Cosmetics, Pharmaceutical industry

Afrin, the #1 doctor and pharmacist recommended nasal spray brand1, announced today the launch of Childrens Afrin, the children's acute medicated nasal spray that works fast and lasts up to 12 hours.

Key Points: 
  • Afrin, the #1 doctor and pharmacist recommended nasal spray brand1, announced today the launch of Childrens Afrin, the children's acute medicated nasal spray that works fast and lasts up to 12 hours.
  • Available in retail stores nationwide, the line of childrens medicated consumer products includes Afrin Extra Moisturizing Stuffy Nose Spray and Afrin No Drip Extra Moisturizing Stuffy Nose Spray.
  • Childrens Afrin provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies.
  • Childrens Afrin Medicated Nasal Sprays are available at mass retail locations.

Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

Retrieved on: 
Monday, November 14, 2022
Biotechnology, General Health, Pharmaceutical, Health, Puberty, Multimedia, Headache, Urinary incontinence, Overactive bladder, Incontinence, Nasal congestion, Mayo Clinic, Upper respiratory tract infection, Vitamin, Digoxin, PureWow, Lisa Filipetto, Urinary urgency, InStyle, Partnership, Liver, Family medicine, Vibegron, Good Housekeeping, THINX, Travel, Diarrhea, Publication, FDA, Sore throat, Kidney, OAB, Commercial, Orange County Business Journal, WWD, Menstruation, Urine, PLOS One, Urination, Breast milk, NYSE, Medicine, Thinx, Science, Urinary retention, BioMed Central, Nausea, The Journal of Urology, Allergy, Research, 100 Best Workplaces in Europe, Urinary tract infection, Gesellschaft mit beschränkter Haftung, Leakage, Patient, Pharmaceutical industry, Phosphorus, Management, Dietary supplement, Medical device, VideoRay UROVs, Urology

View the full release here: https://www.businesswire.com/news/home/20221114005347/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221114005347/en/
    Urovant Sciences Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season (Graphic: Business Wire)
    November is Bladder Health Awareness Month and its also the start of holiday and winter travel.
  • To help people learn more about OAB and ways to manage symptoms, a free travel kit is available on TimeToGo.com.
  • Overactive bladder (OAB) is a clinical condition that occurs when the bladder muscle contracts involuntarily.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Perception, Gesellschaft mit beschränkter Haftung, Medicine, Overactive bladder, Plasma, Liver, Breast milk, Instagram, Safety, 100 Best Workplaces in Europe, Vitamin, Taste, AES, Headache, AUC, Kopp, Adult, Orange County Business Journal, Drug development, I, Sex, Diarrhea, Digoxin, Neurogenic bladder dysfunction, FDA, Burden, Patient, Food additive, Urination, Food, Kidney, Urinary incontinence, Man, Science, Twitter, OAB, Urinary urgency, Vibegron, Nausea, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sore throat, Urine, Urinary retention, Prevalence, NYSE, Upper respiratory tract infection, Nasal congestion, Urinary tract infection, Vats, Allergy, Dysphagia, Nocturia, Constipation, Public health, Pharmaceutical industry, Medical imaging, Perfume, Dietary supplement, Sexton, Cmax

In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.

Key Points: 
  • In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.
  • All patients received one treatment with intact tablet and one with crushed tablet, mixed with applesauce.
  • Additional reported TEAEs experienced by 2 participants were constipation (crushed, 13.3%; intact 6.7%) and nausea (crushed 6.7%, intact 0%) .
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Pediatric Tech Start-Up is Disrupting RSV Season with Hospital-Grade Suction at Home

Retrieved on: 
Monday, October 24, 2022
Child, Urinary tract infection, National Down Syndrome Congress, Pneumonia, Parent, RSV, Nasal congestion, Primary Children's Hospital, Nose, The Doctor Is In, Down syndrome, Bronchiolitis, Edwards A. Park (doctor), NICU, Down, Otorhinolaryngology, Running, Fever, Degenerative disease, Solution, Toy

ATLANTA, Oct. 24, 2022 /PRNewswire/ -- Dr. Noze Best, an emerging tech company focusing on pediatric wellness, is helping families battle RSV with its flagship product, the NozeBot. It's the first portable and rechargeable hospital-grade nasal aspirator developed in the U.S. for children. Designed from the brand's mission to help infants and toddlers breathe better, the NozeBot's innovative features take the stress out of snot.

Key Points: 
  • Designed from the brand's mission to help infants and toddlers breathe better, the NozeBot's innovative features take the stress out of snot.
  • RSV is a highly contagious virus that can lead to respiratory illness in babies, including lung infections like bronchiolitis and pneumonia.
  • While RSV can begin with cold-like symptoms such as coughing, running nose, and fever, parents should know it can become much more severeeven life-threatening.
  • RSV is the leading cause of hospitalizations in infants under age one and results in 57,000 hospitalizations in children under age five.

Urovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)

Retrieved on: 
Wednesday, September 7, 2022
Clinical Trials, Human Resources, Biotechnology, Seniors, Other Science, Health, Research, Professional Services, Consumer, Publishing, Science, Nursing, Communications, Medical Supplies, Other Health, FDA, Practice Management, Physical Therapy, Managed Care, Pharmaceutical, Business, Medical Devices, Infectious Diseases, Hospitals, Fitness & Nutrition, People, Work, CEO, Man, Culture, Kopp, I, Upper respiratory tract infection, Organization, Urinary retention, Urinary urgency, Medicine, Urine, Overactive bladder, Twitter, Orange County Business Journal, Adult, Gesellschaft mit beschränkter Haftung, Nausea, Patient, Health, Sex, Great Places, Kidney, The Last Best Place, Vitamin, Headache, FDA, Nasal congestion, Diarrhea, Public health, Liver, LinkedIn, Multimedia, Instagram, Breast milk, 100 Best Workplaces in Europe, Sore throat, NYSE, Urinary tract infection, Vats, Achievement, Urinary incontinence, Urination, Allergy, Digoxin, Neurogenic bladder dysfunction, Nocturia, Burden, Feedback, Place, OAB, Health insurance, Management, Pharmaceutical industry, Risk management, Dietary supplement, Biopharma LLC, Sexton, Fortune, VideoRay UROVs

Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .

Key Points: 
  • Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .
  • Its an honor to be recognized by Fortune and Great Place to Work, said James Robinson, CEO of Urovant Sciences.
  • The Fortune Best Workplaces in BioPharma list is highly competitive.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo and Powered by People and Possibilities are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Electrosurgical Devices Market to Reach $8451.68 Million, Globally, by 2028 at 5.68% CAGR Says Brandessence Market Research

Retrieved on: 
Wednesday, September 7, 2022
Liver cancer, Burns, Conditional sentence, Hospital, HPV, Heat, Government, Smoke, Time, Asthma, Virus, Critical care, Tissue, Infection, Laser, Surgeon, Electrosurgery, Prevalence, Nasal congestion, Defibrillation, Nursing, Invention, Risk, Injury, Eye, Growth, Bacteria, Cough, Patient, Coagulation, Dentistry, Medical device

The electrosurgery devices like active electrodes and generators are making it easier and less time consuming for performing such procedures.

Key Points: 
  • The electrosurgery devices like active electrodes and generators are making it easier and less time consuming for performing such procedures.
  • There is production of surgical smoke by the destruction of tissues by use of lasers or the electrosurgical devices.
  • Electrosurgical devices statistics suggest that the North American region is going to account for the biggest share of the electrosurgery market.
  • On Special Requirement Electrosurgical Devices Market Report is also available for below region: